Study to Evaluate the Safety and Efficacy of Vesatolimod in Antiretroviral Treated Human Immunodeficiency Virus (HIV-1) Infected Controllers
A Phase 1b, Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of GS-9620 in Antiretroviral Treated HIV-1 Infected Controllers
Sponsor: Gilead Sciences
This PHASE1 trial investigates HIV-1 Infection and is currently completed. Gilead Sciences leads this study, which shows 18 recorded versions since 2017 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
18 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
May 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Jan 2021 — May 2021 [monthly]
Completed PHASE1
▶ Show 13 earlier versions
-
Apr 2020 — Jan 2021 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Oct 2019 — Apr 2020 [monthly]
Active Not Recruiting PHASE1
-
Apr 2019 — Oct 2019 [monthly]
Active Not Recruiting PHASE1
-
Oct 2018 — Apr 2019 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Sep 2018 — Oct 2018 [monthly]
Recruiting PHASE1
-
Aug 2018 — Sep 2018 [monthly]
Recruiting PHASE1
-
Jul 2018 — Aug 2018 [monthly]
Recruiting PHASE1
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE1
-
Oct 2017 — Jun 2018 [monthly]
Recruiting PHASE1
-
Sep 2017 — Oct 2017 [monthly]
Recruiting PHASE1
-
Aug 2017 — Sep 2017 [monthly]
Recruiting PHASE1
-
Jun 2017 — Aug 2017 [monthly]
Recruiting PHASE1
-
May 2017 — Jun 2017 [monthly]
Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Gilead Sciences
For direct contact, visit the study record on ClinicalTrials.gov .